NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal

Baricitinib for treating juvenile idiopathic arthritis in children and young people aged 1 to 17 ID6143

Provisional Stakeholder List

Consultees	Commentators (no right to submit or appeal)
Company • Eli Lilly & Company (baricitinib) Patient/carer groups • Action on Pain • Arthritis Action • Arthritis and Musculoskeletal Alliance • Children's Chronic Arthritis Association • National Rheumatoid Arthritis Society • Pain Concern • Pain Relief Foundation • Pain UK • Psoriasis and Psoriatic Arthritis Alliance • South Asian Health Foundation • Specialised Healthcare Alliance • Versus Arthritis Professional groups • British Institute of Musculoskeletal Medicine • British Orthopaedic Association • British Paediatric and Adolescent Bone Group • British Pain Society • British Society for Children's Orthopaedic Surgery • British Society for Paediatric and Adolescent Rheumatology • British Society for Rheumatology • British Society of Rehabilitation Medicine • Chartered Society of Physiotherapy • Neonatal and Paediatric Pharmacists Group	General • All Wales Therapeutics and Toxicology Centre • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Confederation • Scottish Medicines Consortium • Welsh Government • Welsh Health Specialised Services Committee Possible comparator companies • AbbVie (adalimumab) • Accord Healthcare UK (methotrexate) • Advanz Pharma (methotrexate) • Amgen UK (adalimumab) • Biogen (adalimumab, etanercept, infliximab) • Bristol-Myers Squibb Pharmaceuticals (abatacept) • Celltrion Healthcare UK (adalimumab, infliximab, rituximab) • Cipla EU (methotrexate) • Fresenius Kabi (adalimumab) • Hospira UK (methotrexate) • Medac GmbH (methotrexate)

Consultees	**Commentators (no right to submit or appeal)**
• Physiotherapy Pain Association • Primary Care Rheumatology and Musculoskeletal Medicine Society • Rheumatoid Arthritis Surgical Society • Royal College of General Practitioners • Royal College of Nursing • Royal College of Paediatrics and Child Health • Royal College of Pathologists • Royal College of Physicians • Royal Pharmaceutical Society • Royal Society of Medicine • Society and College of Radiographers • UK Clinical Pharmacy Association <u>Others</u> • Department of Health and Social Care • NHS England	• Merck Sharpe & Dohme (infliximab) • Morningside Healthcare Ltd (methotrexate) • Mylan UK (adalimumab) • Napp Pharmaceuticals (rituximab) • Nordic Pharma (methotrexate) • Orion Pharma UK (methotrexate) • Pfizer (etanercept, infliximab, methotrexate, rituximab, tofacitinib) • Roche Products (rituximab, tocilizumab) • Rosemont Pharmaceuticals (methotrexate) • Sandoz (adalimumab, etanercept, infliximab, methotrexate, rituximab) • Swedish Orphan Biovitrum (anakinra) • Therakind (methotrexate) <u>Relevant research groups</u> • Bone Research Society • British Psoriatic Arthritis Consortium • Chronic Pain Policy Coalition • Cochrane Musculoskeletal Group • Cochrane UK • Genomics England • MRC Clinical Trials Unit • National Institute for Health Research • Orthopaedic Research UK • Society of Back Pain Research <u>Associated Public Health groups</u> • Public Health Wales • UK Health Security Agency

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement[1], respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.

[1] Non-company consultees are invited to submit statements relevant to the group they are representing.